OVA Peptide 257-264 |
| Catalog No.GC33448 |
OVA 펩티드 257-264는 OVA의 클래스 I(Kb)-제한된 펩티드 에피토프이며, 팔량체 펩티드는 클래스 I MHC 분자, H-2Kb에 의해 제시된 오브알부민에서 유래할 수 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 138831-86-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
OVA Peptide (257-264) is an MHC Class I (Kb) -restricted OVA polypeptide epitope, an octapeptide derived from ovalbumin presented by Class I MHC molecule H-2Kb.It can be used to stimulate T cell activation and activate the immune response of CD8+ cytotoxic T lymphocytes (CTL) [1-3].
OVA peptide (257-264) (injected intradermally at the base of the tail) combined with anti-CD4-monoclonal antibody increased the number of peptide-specific CTLs and showed a higher therapeutic effect against OVA-expressing tumors in mice[4]. Spleen cells pulsed with OVA peptide (257-264)( 250 μg-1mg) are sensitive to Poria cocos polysaccharide (PCP) [5]. OVA peptide (257-264) can be used as a self-assembled nanovaccine (I-OVA NE), which enhances peptid-specific CD8+T cells and exhibits ova257-264 specific CTL activity and Th1 immune response[6]. Mice anterior chamber inoculation of OVA Peptide (257-264) (250 μg) could induceanterior chamber associated immune deviation (ACAID) as evidenced by an impaired delayed-type hypersensitivity (DTH) response[7].
References:
[1]. Wick MJ, Pfeifer JD. Major histocompatibility complex class I presentation of ovalbumin peptide 257-264 from exogenous sources: protein context influences the degree of TAP-independent presentation. Eur J Immunol. 1996 Nov;26(11):2790-9. doi: 10.1002/eji.1830261135. PMID: 8921970.
[2]. Doherty PC, Christensen JP. Accessing complexity: the dynamics of virus-specific T cell responses. Annu Rev Immunol. 2000;18:561-92. doi: 10.1146/annurev.immunol.18.1.561. PMID: 10837069.
[3]. Grolleau-Julius A, Harning EK,et,al. Impaired dendritic cell function in aging leads to defective antitumor immunity. Cancer Res. 2008 Aug 1;68(15):6341-9. doi: 10.1158/0008-5472.CAN-07-5769. PMID: 18676859; PMCID: PMC2575813.
[4]. Fujinami N, Yoshikawa T, et,al. Enhancement of antitumor effect by peptide vaccine therapy in combination with anti-CD4 antibody: Study in a murine model. Biochem Biophys Rep. 2016 Feb 19;5:482-491. doi: 10.1016/j.bbrep.2016.02.010. PMID: 28955856; PMCID: PMC5600353.
[5]. Dong X, Li B, et,al. Poria cocos polysaccharide induced Th1-type immune responses to ovalbumin in mice. PLoS One. 2021 Jan 7;16(1):e0245207. doi: 10.1371/journal.pone.0245207. PMID: 33411807; PMCID: PMC7790389.
[6]. Yang Y, Ge S, et,al. A novel self-assembled epitope peptide nanoemulsion vaccine targeting nasal mucosal epithelial cell for reinvigorating CD8+ T cell immune activity and inhibiting tumor progression. Int J Biol Macromol. 2021 Jul
31;183:1891-1902. doi: 10.1016/j.ijbiomac.2021.05.158. Epub 2021 May 27. PMID: 34052270.
[7]. Ren Y, Yang P, et,al. OVA-specific CD8+ T cells do not express granzyme B during anterior chamber associated immune deviation. Graefes Arch Clin Exp Ophthalmol. 2006 Oct;244(10):1315-21. doi: 10.1007/s00417-006-0255-0. Epub 2006 Mar 15. PMID: 16538449.
Average Rating: 5 (Based on Reviews and 29 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *